1Hislop AD, Taylor GS, Sauce D, et al. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus[J]. Annu Rev Immunol, 2007, 25: 587-617.
3Griffin BE. Epstein-Barr virus (EBV) and human disease: facts, opinions and problems. [J]. Mutat Res, 2000, 462 (2-3): 395-405.
4Okano M. Haematological associations of epstein-barr virus infection[J]. Baillieres Best Pract Res Clin Haema- tol, 2000, 13(2): 199-214.
5Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of epstein-barr virus mimics a constitutively active receptor molecule[J]. EMBO J, 1997, 16 (20): 6131-6140.
6Uchida J, Yasui T, Takaoka-Shichijo Y, et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. [J]. Science, 1999, 286(5438): 300-303.
7Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system[J]. Nat Rev Immunol, 2001, 1(1): 75-82.
8Miller CL, Burkhardt AL, Lee JH, et al. Integral mem- brane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases [J]. Immunity, 1995, 2(2): 155-166.
9Yates J, Warren N, Reisman D, et al. A cis-acting element from the epstein-barr viral genome that permits stable replication of recombinant plasmids in latently infected cells [J]. Proc Natl Acad Sci USA, 1984, 81 (12): 3806-3810.
10Johannsen E, Koh E, Mosialos G, et al. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1[J]. J Virol, 1995, 69(1): 253-262.
